The abstract is read at the publisher; the summary is JClub's.
Pseudomonas aeruginosa clinical strains show two major barriers to Pbunavirus phage therapy—receptor masking by O-antigen and intracellular defenses that block Pbunavirus DNA replication.
- Why it matters: When a clinical strain resists a phage before treatment, it is unclear which mechanisms limit phage success, making rational enhancement difficult.
- What they did: Broad host range Pbunavirus phages were tested against clinical strains, and unbiased genome-wide CRISPRi screens identified the broadly conserved L-rhamnose in the core polysaccharide as the receptor, often masked by diverse O-antigen structures.
- The result: In some strains, intracellular defenses prevent Pbunavirus DNA replication, but intrafamily engineering using multiple genes from a variable Pbunavirus anti-defense island enhanced phage replication in some clinical strains.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.